GenoLogics secures $8 million in strategic financing

Friday, October 21, 2011 02:14 PM

GenoLogics has raised $8 million in strategic financing led by new investor Illumina. The financing will be used to accelerate product development for future clinical applications and new desktop sequencing systems, and to expand sales and marketing functions.

Illumina senior vice president and chief commercial officer Tristan Orpin will also be joining GenoLogics' board of directors.

"This strategic investment in GenoLogics will benefit our mutual sequencing customers," said Illumina's Orpin. "We value the unique data management capabilities GenoLogics brings to our customers and the industry."

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs